The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...
A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas ...
This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, ...
Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...
The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...
The FDA has granted orphan drug designation (ODD) to LP-284, a next-generation acylfulvene small molecule, for the treatment ...
Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in high-risk resected melanoma ...
The FDA has granted breakthrough therapy designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of patients ...
The NCCN guidelines now include MammaPrint for identifying HR+/HER2- early-stage breast cancer patients who may benefit from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback